GlassScriptPhysician profile
James S Carr
NPI 1316918238
$2,721.12
in general payments reported to CMS, 2019-2025
23 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.44 · 2020: $160 · 2021: $720 · 2022: $605 · 2023: $514 · 2024: $355 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.07 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $748.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $408.50 | 2019-2025 | Qulipta, Botox, Orilissa |
| Ascend Therapeutics US, LLC | $206.41 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $162.62 | 2022-2025 | |
| Astellas Pharma US INC | $150.45 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $149.64 | 2021-2025 | Zepbound |
| Pfizer INC. | $144.18 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $136.79 | 2020-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Axonics, INC. | $108.61 | 2021 | |
| Myovant Sciences INC. | $84.03 | 2021-2022 | |
| Millicent US INC | $61.01 | 2024-2025 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $57.76 | 2020-2022 | |
| Galderma Laboratories, L.P. | $44.69 | 2020 | |
| Allergan, INC. | $39.58 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $38.12 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.23 | 2020-2021 | |
| Therapeuticsmd, INC. | $31.27 | 2020-2022 | |
| Avion Pharmaceuticals | $27.64 | 2022-2023 | Balcoltra |
| Bausch Health US, LLC | $23.13 | 2022 | |
| Hologic Sales and Service, LLC | $21.79 | 2025 | Aptima |
| Evofem Biosciences, INC. | $17.74 | 2022 | |
| Eisai INC. | $13.34 | 2021 | |
| Amgen INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.